Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

760 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases.
Castellano I, Sapino A, Arisio R, Viale G, Bussolati G, Bandelloni R, Barresi G, Bersiga A, Bordi C, Botti G, Cosimi F, D'Amore E, Doglioni C, Marchetti A, Nappi O, Romeo F, Roncalli M, Russo R, Santinelli A, Spagnoli LG, Tanda F, Tricomi P, Trentini G, Zanconati F, Iurlaro M. Castellano I, et al. Among authors: botti g. Oncol Rep. 2008 May;19(5):1271-5. Oncol Rep. 2008. PMID: 18425387
Basic principles of biobanking: from biological samples to precision medicine for patients.
Annaratone L, De Palma G, Bonizzi G, Sapino A, Botti G, Berrino E, Mannelli C, Arcella P, Di Martino S, Steffan A, Daidone MG, Canzonieri V, Parodi B, Paradiso AV, Barberis M, Marchiò C; Alleanza Contro il Cancro (ACC) Pathology and Biobanking Working Group. Annaratone L, et al. Among authors: botti g. Virchows Arch. 2021 Aug;479(2):233-246. doi: 10.1007/s00428-021-03151-0. Epub 2021 Jul 13. Virchows Arch. 2021. PMID: 34255145 Free PMC article. Review.
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Clavarezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M. Montemurro F, et al. Among authors: botti g. Clin Breast Cancer. 2008 Oct;8(5):436-42. doi: 10.3816/CBC.2008.n.053. Clin Breast Cancer. 2008. PMID: 18952558
CD40 activation as potential tool in malignant neoplasms.
Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR. Ottaiano A, et al. Among authors: botti g. Tumori. 2002 Sep-Oct;88(5):361-6. doi: 10.1177/030089160208800502. Tumori. 2002. PMID: 12487551 Review.
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.
Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M, Botti G. Collina F, et al. Among authors: botti g. Biomed Res Int. 2015;2015:158682. doi: 10.1155/2015/158682. Epub 2015 Oct 4. Biomed Res Int. 2015. PMID: 26504780 Free PMC article.
18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.
Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S. Avallone A, et al. Among authors: botti g. J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877175 Free PMC article. Clinical Trial.
760 results